ArticleStem cell research & therapy2025
AMSC-EVs attenuate acute kidney injury through TXNIP-IKKα/NFκB signaling-mediated renal CX3CR1
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Macrophage autophagy-dependent M2 polarization mediates the protective effect of ADSC-conditioned medium against acute lung injury.Stem cell research & therapy · 2026Article
- Spatiotemporal Control of Intercellular Crosstalk: A New Therapeutic Paradigm for Halting Acute Kidney Injury to Chronic Kidney Disease Transition.Biomolecules · 2026Review
- Advancing mesenchymal stem cell therapy for kidney diseases in companion animals: from mechanisms to clinical application.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundExtracellular vesicles generated from mesenchymal stem cells (MSC-EVs) have garnered significant attention as a cell-free treatment option for acute kidney injury (AKI). The fundamental processes and capabilities of MSC-EVs in attenuating kidney injury are still largely unclear.
methodsThe AKI mouse model was established by intraperitoneal injection of cisplatin. AKI mice were further randomized to receive Phosphate- Buffered Saline, adipose-derived mesenchymal stem cell-extracellular vesicles (AMSC-EVs (50 µg), or AMSC-EVs (100 µg) into the tail vein. Following a 96-hour post-injury period, the mice were euthanized, and kidney tissues together with blood samples were procured for paraffin embedding and immunoblotting. To investigate the relationship between AMSC-EVs and renal CX3CR1
resultsIn mice, AMSC-EVs reduced the renal tubule damage and ameliorated cisplatin-induced AKI in a dose-dependent manner. However, in the CX3CR1
conclusionsOur study findings suggest that AMSC-EVs modulate the polarization of renal CX3CR1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.